Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Considerations in selecting protease inhibitor therapy.

Brian A Boyle1, Richard A Elion, Graeme J Moyle

  • 1Weill Medical College of Cornell University, New York, NY 10021, USA. brianboylemd@yahoo.com

AIDS Reviews
|February 11, 2005
PubMed
Summary

Highly active antiretroviral therapy (HAART) with protease inhibitors has improved HIV outcomes. Newer protease inhibitors offer simpler, more effective, and safer treatment options for HIV patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and Outcomes.

AIDS patient care and STDs·2026
Same author

Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort study.

AIDS research and therapy·2025
Same author

Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.

AIDS (London, England)·2025
Same author

A pseudo-response approach to constructing confidence intervals for the subset of patients expected to benefit from a new treatment.

Journal of the Royal Statistical Society. Series C, Applied statistics·2024
Same author

A Comparison of Self-reported Pain Measures Between Sensory Phenotypes in HIV-associated Sensory Neuropathy.

The journal of pain·2022
Same author

Statins Utilization in Adults With HIV: The Treatment Gap and Predictors of Statin Initiation.

Journal of acquired immune deficiency syndromes (1999)·2022

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Protease inhibitors (PIs) are crucial components of highly active antiretroviral therapy (HAART) for HIV-infected individuals.
  • Early PIs presented challenges including limited efficacy, side effects, complex regimens, and cross-resistance.
  • Significant advancements have been made in PI development over the last decade.

Purpose of the Study:

  • To review the evolution and impact of protease inhibitors in HIV treatment.
  • To highlight improvements in PI-based HAART regimens.
  • To emphasize considerations for selecting optimal PIs for long-term patient management.

Main Methods:

  • Review of clinical literature and drug development advancements in protease inhibitors.

Related Experiment Videos

  • Analysis of efficacy, tolerability, and resistance profiles of early and newer PIs.
  • Consideration of treatment regimen complexity and patient-centered factors.

    • Main Results:

    • Advances like ritonavir boosting and once-daily dosing PIs have enhanced HAART.
    • Newer PIs demonstrate improved efficacy, reduced toxicity, and lower resistance risk.
    • Simplified and better-tolerated PI therapy is now achievable.

    Conclusions:

    • Modern protease inhibitor-based HAART offers significant benefits over earlier regimens.
    • Individualized selection of PIs, considering drug characteristics and patient preference, is key.
    • Optimizing PI choice maximizes long-term treatment success and tolerability in HIV management.